Metoclopramide side effects: what 54,571 FDA adverse event reports show
Drug class
Not stated in label
Who reports
54,571 reports · 94% serious · 7,242 with death outcome · 62% female
Used for
Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. Relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
What it is
Metoclopramide hydrochloride, USP, the active ingredient of metoclopramide tablets, USP is a dopamine-2 receptor antagonist. Metoclopramide hydrochloride (metoclopramide monohydrochloride monohydrate) is a white or practically white, crystalline, odorless or practically odorless powder.
Boxed warning
TARDIVE DYSKINESIA Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. There is no known treatment for TD. The risk of developing TD increases with duration of treatment and total cumulative dosage [ see Warnings and Precautions ( 5.1 ) ].
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,190 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Computerised tomogram thorax | 39 | 702.3 413.2–1,193.7ROR 702.8 · calibrated p 7e-14 ✓ | 220.0 EB05 167.9 · IC025 +5.4 3/3 methods agree | Not in label — unassessed | serious n=39 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
| Family stress | 1,920 | 615.8 573.0–661.8ROR 638.2 · calibrated p 4e-15 ✓ | 234.4 EB05 225.7 · IC025 +7.7 3/3 methods agree | Not in label — unassessed | serious n=1,920 | no trial arm names this drug |
| Extrapyramidal disorder | 11,637 | 335.5 327.7–343.4ROR 426.1 · calibrated p 3e-13 ✓ | 178.2 EB05 175.5 · IC025 +7.4 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 8.4 · serious PRR 118.3 · 73% consumer | no trial arm names this drug |
| Tardive dyskinesia (persistent involuntary movements) | 13,206 | 335.0 327.7–342.4ROR 441.6 · calibrated p 2e-13 ✓ | 178.0 EB05 175.5 · IC025 +7.4 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 127.8 · 78% consumer | no trial arm names this drug |
| Dystonia | 6,682 | 201.7 196.0–207.5ROR 229.7 · calibrated p 1e-10 ✓ | 131.8 EB05 129.2 · IC025 +7.0 3/3 methods agree | Not in label — unassessed | serious PRR 88.1 | no trial arm names this drug |
| Multiple injuries | 2,127 | 193.1 183.4–203.3ROR 200.9 · calibrated p 4e-10 ✓ | 128.0 EB05 123.5 · IC025 +6.9 3/3 methods agree | Not in label — unassessed | serious n=2,126 · 100% consumer | no trial arm names this drug |
| Grimacing | 222 | 153.8 131.6–179.7ROR 154.4 · calibrated p 4e-9 ✓ | 108.6 EB05 97.1 · IC025 +6.2 3/3 methods agree | Labeled adverse reaction exact term | serious n=220 | no trial arm names this drug |
| Deformity | 2,327 | 127.1 121.4–133.1ROR 132.7 · calibrated p 1e-8 ✓ | 95.3 EB05 92.1 · IC025 +6.5 3/3 methods agree | Not in label — unassessed | serious PRR 66.5 · 100% consumer | no trial arm names this drug |
| Economic problem | 3,755 | 124.0 119.6–128.5ROR 133.0 · calibrated p 1e-8 ✓ | 93.6 EB05 91.1 · IC025 +6.5 3/3 methods agree | Reporting / coding artifact | serious PRR 61.7 · 100% consumer | no trial arm names this drug |
| Nervous system disorder | 7,176 | 114.4 111.5–117.3ROR 131.5 · calibrated p 1e-8 ✓ | 88.0 EB05 86.3 · IC025 +6.4 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.4 · serious PRR 60.0 | no trial arm names this drug |
| Excessive eye blinking | 284 | 91.4 80.3–104.0ROR 91.9 · calibrated p 2e-7 ✓ | 73.5 EB05 66.6 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious n=283 | no trial arm names this drug |
| Vaginal flatulence | 52 | 78.7 58.4–106.0ROR 78.7 · calibrated p 1e-6 ✓ | 63.8 EB05 50.5 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=52 · ♀ 100% (drug 62%) | no trial arm names this drug |
| Quality of life decreased | 2,038 | 68.7 65.6–71.9ROR 71.3 · calibrated p 1e-6 ✓ | 58.2 EB05 56.2 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious PRR 43.7 | no trial arm names this drug |
| Activities of daily living impaired | 2,759 | 61.1 58.8–63.6ROR 64.3 · calibrated p 3e-6 ✓ | 52.8 EB05 51.1 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious PRR 43.2 · 71% consumer | no trial arm names this drug |
| Parkinson's disease | 332 | 56.7 50.6–63.6ROR 57.1 · calibrated p 6e-6 ✓ | 49.3 EB05 45.0 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=311 | no trial arm names this drug |
| Essential tremor | 135 | 52.8 44.1–63.2ROR 52.9 · calibrated p 1e-5 ✓ | 46.2 EB05 40.0 · IC025 +5.0 3/3 methods agree | Labeled (related wording) related wording | serious n=128 | no trial arm names this drug |
| Akathisia (inner restlessness) | 1,614 | 51.5 48.9–54.2ROR 53.0 · calibrated p 9e-6 ✓ | 45.4 EB05 43.6 · IC025 +5.4 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 38.8 | no trial arm names this drug |
| Chorea | 184 | 45.7 39.2–53.2ROR 45.8 · calibrated p 3e-5 ✓ | 40.7 EB05 36.0 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=174 | no trial arm names this drug |
| Depression suicidal | 364 | 45.1 40.5–50.3ROR 45.4 · calibrated p 3e-5 ✓ | 40.3 EB05 37.0 · IC025 +5.1 3/3 methods agree | Labeled (related wording) related wording | serious n=359 | no trial arm names this drug |
| Peripheral circulatory failure | 43 | 45.0 32.8–61.8ROR 45.1 · calibrated p 4e-5 ✓ | 39.7 EB05 30.7 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=43 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
| Computerised tomogram thorax abnormal | 71 | 43.5 34.0–55.6ROR 43.6 · calibrated p 4e-5 ✓ | 38.8 EB05 31.8 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=71 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
| Movement disorder | 2,870 | 37.5 36.1–38.9ROR 39.5 · calibrated p 6e-5 ✓ | 34.2 EB05 33.1 · IC025 +5.0 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 1.2 · serious PRR 26.6 · 73% consumer | no trial arm names this drug |
| Incorrect drug administration duration | 2,488 | 36.7 35.2–38.2ROR 38.4 · calibrated p 7e-5 ✓ | 33.5 EB05 32.4 · IC025 +5.0 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 0.2 · serious PRR 56.0 · 100% consumer | no trial arm names this drug |
| Multiple drug therapy | 57 | 34.1 26.0–44.7ROR 34.1 · calibrated p 2e-4 ✓ | 31.1 EB05 24.9 · IC025 +4.2 3/3 methods agree | Reporting / coding artifact | serious n=57 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
| Stereotypy | 76 | 33.9 26.8–42.8ROR 33.9 · calibrated p 2e-4 ✓ | 30.9 EB05 25.5 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=75 | no trial arm names this drug |
| Pre-existing disease | 38 | 32.0 23.0–44.6ROR 32.0 · calibrated p 3e-4 ✓ | 29.2 EB05 22.2 · IC025 +3.9 3/3 methods agree | Reporting / coding artifact | serious n=38 · ♀ 100% (drug 62%) | no trial arm names this drug |
| Partner stress | 72 | 30.9 24.3–39.2ROR 30.9 · calibrated p 3e-4 ✓ | 28.4 EB05 23.3 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=71 | no trial arm names this drug |
| Protrusion tongue | 43 | 30.8 22.6–42.0ROR 30.8 · calibrated p 3e-4 ✓ | 28.2 EB05 21.8 · IC025 +3.9 3/3 methods agree | Labeled (related wording) related wording | serious n=41 | no trial arm names this drug |
| Dyskinesia (involuntary movements) | 2,561 | 25.8 24.9–26.9ROR 27.1 · calibrated p 4e-4 ✓ | 24.3 EB05 23.5 · IC025 +4.5 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 3.2 · serious PRR 19.4 | no trial arm names this drug |
| Fear | 1,691 | 25.5 24.3–26.8ROR 26.3 · calibrated p 5e-4 ✓ | 24.0 EB05 23.0 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | age-adj. PRR 1.2 · serious PRR 19.8 | no trial arm names this drug |
| Anhedonia | 1,637 | 25.3 24.0–26.5ROR 26.0 · calibrated p 6e-4 ✓ | 23.7 EB05 22.8 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious PRR 16.0 · 100% consumer | no trial arm names this drug |
| Metabolic disorder | 329 | 23.0 20.6–25.7ROR 23.2 · calibrated p 0.001 ✓ | 21.8 EB05 19.8 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=328 | no trial arm names this drug |
| Phaeochromocytoma | 35 | 21.3 15.1–29.9ROR 21.3 · calibrated p 0.002 ✓ | 20.0 EB05 15.0 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=35 · ♀ 100% (drug 62%) · 100% clinician | no trial arm names this drug |
| Aplastic anaemia | 265 | 20.4 18.0–23.1ROR 20.5 · calibrated p 0.002 ✓ | 19.4 EB05 17.5 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=265 · 95% clinician | no trial arm names this drug |
| Neutropenic sepsis | 360 | 20.3 18.3–22.6ROR 20.4 · calibrated p 0.002 ✓ | 19.3 EB05 17.7 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious PRR 11.7 · 94% clinician | no trial arm names this drug |
| Parkinsonism | 445 | 18.3 16.7–20.2ROR 18.5 · calibrated p 0.003 ✓ | 17.5 EB05 16.2 · IC025 +3.9 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 12.1 | no trial arm names this drug |
| Systemic infection | 75 | 18.1 14.4–22.8ROR 18.1 · calibrated p 0.003 ✓ | 17.2 EB05 14.2 · IC025 +3.6 3/3 methods agree | Labeled adverse reaction exact term | serious n=75 · ♀ 29% (drug 62%) · 100% clinician | no trial arm names this drug |
| Nephrogenic anaemia | 200 | 17.1 14.9–19.7ROR 17.2 · calibrated p 0.004 ✓ | 16.4 EB05 14.6 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=200 | no trial arm names this drug |
| Hyperparathyroidism secondary | 105 | 16.6 13.6–20.2ROR 16.6 · calibrated p 0.005 ✓ | 15.9 EB05 13.5 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=105 | no trial arm names this drug |
| Chronic kidney disease-mineral and bone disorder | 40 | 14.8 10.8–20.3ROR 14.8 · calibrated p 0.009 ✓ | 14.0 EB05 10.6 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=40 | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Extrapyramidal | 15,201 | 64.863.8–65.7 | signal |
| Neutropenia / agranulocytosis | 3,284 | 5.25.0–5.3 | signal |
| Hyponatraemia | 798 | 3.83.6–4.1 | signal |
| Severe cutaneous reaction | 527 | 2.72.5–3.0 | signal |
| Kidney injury | 3,204 | 2.72.6–2.8 | signal |
| Anaemia | 2,098 | 2.72.6–2.8 | signal |
| Arrhythmia / qt | 1,231 | 2.52.3–2.6 | signal |
| Thrombocytopenia | 1,316 | 2.32.2–2.4 | signal |
| Anaphylaxis / angioedema | 668 | 2.11.9–2.2 | raised |
| Interstitial lung disease | 500 | 2.01.8–2.2 | raised |
| Gi bleeding | 925 | 1.91.8–2.1 | raised |
| Pancreatitis | 390 | 1.91.7–2.1 | raised |
| Serious infection | 3,679 | 1.81.8–1.9 | raised |
| Depression | 1,291 | 1.81.7–1.9 | raised |
| Liver injury | 1,379 | 1.81.7–1.9 | raised |
| Venous thromboembolism | 974 | 1.71.6–1.8 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Tardive dyskinesia (persistent involuntary movements) | 13,206 | 335.0 327.7–342.4ROR 441.6 · calibrated p 2e-13 ✓ | 178.0 EB05 175.5 · IC025 +7.4 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 127.8 · 78% consumer | no trial arm names this drug |
| Extrapyramidal disorder | 11,637 | 335.5 327.7–343.4ROR 426.1 · calibrated p 3e-13 ✓ | 178.2 EB05 175.5 · IC025 +7.4 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 8.4 · serious PRR 118.3 · 73% consumer | no trial arm names this drug |
| Nervous system disorder | 7,176 | 114.4 111.5–117.3ROR 131.5 · calibrated p 1e-8 ✓ | 88.0 EB05 86.3 · IC025 +6.4 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.4 · serious PRR 60.0 | no trial arm names this drug |
| Dystonia | 6,682 | 201.7 196.0–207.5ROR 229.7 · calibrated p 1e-10 ✓ | 131.8 EB05 129.2 · IC025 +7.0 3/3 methods agree | Not in label — unassessed | serious PRR 88.1 | no trial arm names this drug |
| Pain | 4,723 | 3.0 2.9–3.0ROR 3.2 · calibrated p 0.579 | 2.9 EB05 2.9 · IC025 +1.5 3/3 methods agree | Not in label — unassessed | age-adj. PRR 1.2 · serious PRR 2.8 | no trial arm names this drug |
| Nausea | 4,084 | 2.0 1.9–2.1ROR 2.1 · calibrated p 0.984 | 2.0 EB05 1.9 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 2.4 · serious PRR 2.2 | no trial arm names this drug |
| Economic problem | 3,755 | 124.0 119.6–128.5ROR 133.0 · calibrated p 1e-8 ✓ | 93.6 EB05 91.1 · IC025 +6.5 3/3 methods agree | Reporting / coding artifact | serious PRR 61.7 · 100% consumer | no trial arm names this drug |
| Vomiting | 3,262 | 2.7 2.6–2.8ROR 2.8 · calibrated p 0.698 | 2.7 EB05 2.6 · IC025 +1.4 3/3 methods agree | Not in label — unassessed | age-adj. PRR 3.1 · serious PRR 2.3 | no trial arm names this drug |
| Anxiety | 3,214 | 4.4 4.2–4.5ROR 4.6 · calibrated p 0.286 | 4.3 EB05 4.2 · IC025 +2.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 3.8 | no trial arm names this drug |
| Movement disorder | 2,870 | 37.5 36.1–38.9ROR 39.5 · calibrated p 6e-5 ✓ | 34.2 EB05 33.1 · IC025 +5.0 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 1.2 · serious PRR 26.6 · 73% consumer | no trial arm names this drug |
| Diarrhoea (diarrhea) | 2,772 | 1.7 1.6–1.7ROR 1.7 · calibrated p 0.765 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 2.0 · serious PRR 1.7 | no trial arm names this drug |
| Activities of daily living impaired | 2,759 | 61.1 58.8–63.6ROR 64.3 · calibrated p 3e-6 ✓ | 52.8 EB05 51.1 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious PRR 43.2 · 71% consumer | no trial arm names this drug |
| Dyskinesia (involuntary movements) | 2,561 | 25.8 24.9–26.9ROR 27.1 · calibrated p 4e-4 ✓ | 24.3 EB05 23.5 · IC025 +4.5 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 3.2 · serious PRR 19.4 | no trial arm names this drug |
| Incorrect drug administration duration | 2,488 | 36.7 35.2–38.2ROR 38.4 · calibrated p 7e-5 ✓ | 33.5 EB05 32.4 · IC025 +5.0 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 0.2 · serious PRR 56.0 · 100% consumer | no trial arm names this drug |
| Deformity | 2,327 | 127.1 121.4–133.1ROR 132.7 · calibrated p 1e-8 ✓ | 95.3 EB05 92.1 · IC025 +6.5 3/3 methods agree | Not in label — unassessed | serious PRR 66.5 · 100% consumer | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Computerised tomogram thorax — n=39, PRR 702.3
- Family stress — n=1,920, PRR 615.8
- Dystonia — n=6,682, PRR 201.7
- Multiple injuries — n=2,127, PRR 193.1
- Deformity — n=2,327, PRR 127.1
- Excessive eye blinking — n=284, PRR 91.4
- Vaginal flatulence — n=52, PRR 78.7
- Quality of life decreased — n=2,038, PRR 68.7
- Activities of daily living impaired — n=2,759, PRR 61.1
- Parkinson's disease — n=332, PRR 56.7
✓ A hand-written Bradford Hill causality assessment exists for this drug: Metoclopramide ↔ Tardive dyskinesia.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Metoclopramide?
In FDA FAERS, the most frequently co-reported reaction terms for Metoclopramide are tardive dyskinesia, extrapyramidal disorder, nervous system disorder, dystonia, pain, nausea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Metoclopramide have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: TARDIVE DYSKINESIA Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. There is no known treatment for TD. The risk of developing TD increases with duration of treatment and total cumulative dosage [ see Warnings and Precautions ( 5.1 ) ].
Do FAERS signals prove that Metoclopramide causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 23f11d3c-1529-4bb6-a61e-e4bab1a3e98e, effective 20240808; matched on
openfda.generic_name.exact:"METOCLOPRAMIDE") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,230 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
METOCLOPRAMIDE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.